Abivax : Full-year results in line - Clinical calendar confirmed
>Financial visibility out to Q4 2025 - The group reported a 2023 operating loss of € 127.4m vs a loss of € 64.8m last year. The difference is explained by operating expenses up by € 63m to € 132m, including € 103.2m (vs €48.3m in 2022) for R&D, € 6.4m (vs € 0m in 2022) for S&M and € 22.4m (vs €7.5m in 2022) for G&A. Cash and cash equivalents were € 261m in December 2023. Including the structured finance with Kreos Capital / Claret, the company is funded until Q4 2025....ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.